Prior Authorization Changes for Some Commercial and Government Program Members
Summary
Blue Cross Blue Shield of New Mexico is restructuring prior authorization and clinical review processes across commercial and government plans, effective in two phases: October 1, 2026 (commercial medical oncology drugs) and January 1, 2027 (genetic testing, sleep services, oncology, orthotics, wound care, and DME codes). Multiple utilization management vendors (Carelon, Evicore, Alacura) will handle different service categories. Additionally, 'recommended clinical review' will be phased out entirely by end of 2027 for most commercial members.
Get alerts when payers change rules like this one
We check BCBS New Mexico and other payers every day and email you when a change matches your specialty and state.